红日药业:PTS不是PD-L1。PTS是一种治疗肺癌、肝癌的新型抗癌药物,是高仿药物还是原创药物暂不详。目前国内市场有同类药物多自美国生产,根据医疗界医生透露,药物控制肺癌有特效,就是价格太贵!红日药业PTS有一种剂型巳经获批印证待发,有一种制型也受理二次发补。如果公司公告PTS获批生产时,那将是这类抗肿瘤药物在中...
红日药业: 血必净注射液的海外注册工作在美国等国家已经启动。 PTS不是PD-L1。PTS是一种治疗肺癌、肝癌的新型抗癌药物,是高仿药物还是原创药物暂不详。目前国内市场有同类药物多自美国生产,根据医疗界医生透露,药物控制肺癌有特效,就是价格太贵!红日药业PTS有一种剂型巳经获批印证待发,有一种制型也受理二次发补。...
红日药业:您好,公司在研一类新药PTS项目仍在进行国家药品监督管理局药审中心的第二次发补的研究和讨论,该项目研发团队正在竭尽全力克服多种困难以最快的速度完成此次发补工作。艾姆地芬片(PD-L1)项目处于一期临床研究阶段。请您持续关注公司的后续公告。感谢您的关注! (来自深交所互动易)答复时间 2020-11-17 16...
PD-L1 expression on TC (1%) was associated with worse OS (22.7 vs 29.1 months, HR=1.51 (1.06-2.15), p=0.0232) but not PFS (3.5 vs 4.6 months, p=0.5121). PD-L1 expression on IC (1%) was associated with numerically shorter median OS (24.7 months vs NR, HR=1.34 (0.95-1.88), p...
Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated find... Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1...
b7 patients died due to PD; 2 did not receive any additional treatment. Conclusions Pembro continues to show improvements in OS vs chemo as 1L treatment for metastatic NSCLC with PD-L1 TPS ≥50%. Despite the high crossover rate, 5-year OS was approximately doubled among pts who received ...
LecturesL01.01NO ABSTRACT AVAILABLEL01.02NO ABSTRACT AVAILABLEL02.01DEVELOPMENT OF MPDL3280A, AN ANTI-PD-L1 ANTIBODY ENGINEERED FOR ENHANCED EFFICACY AND SAFETYL02.02NO ABSTRACT AVAILABLEL02.03NIVOLUMAB (ANTI-PROGRAMMED DEATH-1 [PD-1]; BMS-936558) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS: ...
It is noted that the responses were independent of PD-L1 status. The patients have been on treatment from 6 to more than 42 weeks. Out of 19 patients, 13 patients were still on treatment. AK104 in combination with mXELOX had a manageable safety profile. Of the 21 patients, we observed...
PD-L1 CPS did not correlate with death or disease progression. Among peripheral blood cytokines, increased MCSF levels were associated with prolonged PFS at several timepoints (baseline [p=0.038], post-induction [p=0.031], and at the end of RT [p=0.023]); interval increase in IFNg inducing...
Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors Introduction: Immune checkpoint inhibitors (ICIs) have significantly improved the prognosis of non-small cell lung cancer (NSCLC). However, only a limited ......